Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Marek

Showing results (101-110 of 144) with videos related to

Pageof 15
Sort By:
Clinical Pharmacology and Therapeutics|September 24, 2019
Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial DesignsMalidi Ahamadi, Daniela J Conrado, Sreeraj Macha, et al.
Annals of Neurology|May 7, 2026
How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early-Stage Neuronal Alpha-Synuclein DiseaseTanya Simuni, Christopher S Coffey, Catherine M Kopil, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 31, 2019
Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's diseaseBrit Mollenhauer, Chelsea J Caspell-Garcia, Christopher S Coffey, et al.
Annals of Neurology|May 19, 2026
Outcomes in Long-Term Follow-Up of Sporadic Parkinson's Disease in the Parkinson's Progression Markers InitiativePaulina Gonzalez-Latapi, Caroline Gochanour, Seung Ho Choi, et al.
Journal of Parkinson'S Disease|July 17, 2023
Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease ProgressionMichael C Brumm, Andrew Siderowf, Tanya Simuni, et al.
JAMA Neurology|August 28, 2013
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson diseaseJu-Hee Kang, David J Irwin, Alice S Chen-Plotkin, et al.
Annals of Neurology|June 17, 2020
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's DiseaseDavid J Irwin, Janel Fedler, Christopher S Coffey, et al.
Movement Disorders Clinical Practice|June 19, 2023
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory StudyDaniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, et al.
Annals of Neurology|April 30, 2026
Return of Individual Research Information in the Parkinson's Progression Markers InitiativeThomas F Tropea, Kathryn Brodkin, Michael C Brumm, et al.
Neurology|August 22, 2022
Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the <i>LRRK2</i> G2019S VariantRachel Saunders-Pullman, Roberto Angel Ortega, Cuiling Wang, et al.
Pageof 15

Showing results (101-110 of 144) with videos related to

Sort By:
Pageof 15
Clinical Pharmacology and Therapeutics|September 24, 2019
Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial DesignsMalidi Ahamadi, Daniela J Conrado, Sreeraj Macha, et al.
Annals of Neurology|May 7, 2026
How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early-Stage Neuronal Alpha-Synuclein DiseaseTanya Simuni, Christopher S Coffey, Catherine M Kopil, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 31, 2019
Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's diseaseBrit Mollenhauer, Chelsea J Caspell-Garcia, Christopher S Coffey, et al.
Annals of Neurology|May 19, 2026
Outcomes in Long-Term Follow-Up of Sporadic Parkinson's Disease in the Parkinson's Progression Markers InitiativePaulina Gonzalez-Latapi, Caroline Gochanour, Seung Ho Choi, et al.
Journal of Parkinson'S Disease|July 17, 2023
Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease ProgressionMichael C Brumm, Andrew Siderowf, Tanya Simuni, et al.
JAMA Neurology|August 28, 2013
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson diseaseJu-Hee Kang, David J Irwin, Alice S Chen-Plotkin, et al.
Annals of Neurology|June 17, 2020
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's DiseaseDavid J Irwin, Janel Fedler, Christopher S Coffey, et al.
Movement Disorders Clinical Practice|June 19, 2023
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory StudyDaniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, et al.
Annals of Neurology|April 30, 2026
Return of Individual Research Information in the Parkinson's Progression Markers InitiativeThomas F Tropea, Kathryn Brodkin, Michael C Brumm, et al.
Neurology|August 22, 2022
Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the <i>LRRK2</i> G2019S VariantRachel Saunders-Pullman, Roberto Angel Ortega, Cuiling Wang, et al.
Pageof 15